Agilent Technologies (A) to Release Quarterly Earnings on Wednesday

Agilent Technologies (NYSE:A - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data after the market closes on Wednesday, May 28th. Analysts expect the company to announce earnings of $1.27 per share and revenue of $1.63 billion for the quarter. Agilent Technologies has set its Q2 2025 guidance at 1.250-1.280 EPS and its FY 2025 guidance at 5.540-5.610 EPS.

Agilent Technologies (NYSE:A - Get Free Report) last released its earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.27 by $0.04. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%. The business had revenue of $1.68 billion during the quarter, compared to the consensus estimate of $1.67 billion. On average, analysts expect Agilent Technologies to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Agilent Technologies Stock Performance

Shares of NYSE A traded down $1.07 during trading on Monday, reaching $108.61. 1,690,973 shares of the stock traded hands, compared to its average volume of 1,929,574. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.20 and a quick ratio of 1.66. The stock has a market capitalization of $30.97 billion, a P/E ratio of 24.97, a price-to-earnings-growth ratio of 3.06 and a beta of 1.27. Agilent Technologies has a 52-week low of $96.43 and a 52-week high of $153.84. The company has a 50-day moving average of $109.16 and a 200-day moving average of $126.98.

Agilent Technologies Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 23rd. Shareholders of record on Tuesday, July 1st will be issued a dividend of $0.248 per share. This represents a $0.99 annualized dividend and a yield of 0.91%. The ex-dividend date is Tuesday, July 1st. Agilent Technologies's dividend payout ratio (DPR) is presently 22.76%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on A shares. Robert W. Baird reduced their target price on shares of Agilent Technologies from $159.00 to $140.00 and set an "outperform" rating for the company in a research note on Thursday. TD Cowen lifted their price objective on shares of Agilent Technologies to $135.00 and gave the company a "buy" rating in a research note on Thursday, April 10th. Wells Fargo & Company dropped their target price on Agilent Technologies from $155.00 to $135.00 and set an "overweight" rating on the stock in a research report on Thursday, April 17th. Barclays reduced their price target on Agilent Technologies from $138.00 to $115.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. Finally, Jefferies Financial Group dropped their price objective on Agilent Technologies from $135.00 to $116.00 and set a "hold" rating on the stock in a report on Monday, April 21st. Seven investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Agilent Technologies currently has a consensus rating of "Moderate Buy" and a consensus price target of $141.42.

Insider Transactions at Agilent Technologies

In related news, Director Daniel K. Podolsky sold 1,819 shares of the company's stock in a transaction on Monday, March 31st. The shares were sold at an average price of $116.46, for a total value of $211,840.74. Following the completion of the transaction, the director now directly owns 35,737 shares in the company, valued at approximately $4,161,931.02. The trade was a 4.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Rodney Gonsalves sold 1,908 shares of the firm's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $121.98, for a total value of $232,737.84. Following the sale, the vice president now owns 21,786 shares in the company, valued at $2,657,456.28. The trade was a 8.05% decrease in their position. The disclosure for this sale can be found here.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in A. Geneos Wealth Management Inc. increased its stake in shares of Agilent Technologies by 54.8% during the first quarter. Geneos Wealth Management Inc. now owns 599 shares of the medical research company's stock valued at $70,000 after buying an additional 212 shares during the period. Brighton Jones LLC grew its stake in shares of Agilent Technologies by 6.1% in the fourth quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company's stock worth $626,000 after acquiring an additional 270 shares during the last quarter. Acadian Asset Management LLC grew its stake in shares of Agilent Technologies by 16.5% in the first quarter. Acadian Asset Management LLC now owns 5,352 shares of the medical research company's stock worth $625,000 after acquiring an additional 758 shares during the last quarter. Finally, Jones Financial Companies Lllp increased its holdings in shares of Agilent Technologies by 15.9% during the first quarter. Jones Financial Companies Lllp now owns 5,610 shares of the medical research company's stock valued at $602,000 after acquiring an additional 769 shares in the last quarter.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.